Suppr超能文献

非实性型甲状腺乳头状癌的亚分类:常见类型高危组的识别

Subclassification of non-solid-type papillary thyroid carcinoma identification of high-risk group in common type.

作者信息

Bai Yanhua, Kakudo Kennichi, Li Yaqiong, Liu Zhiyan, Ozaki Takashi, Ito Yasuhiro, Kihara Minoru, Miyauchi Akira

机构信息

Department of Human Pathology, Wakayama Medical University, Wakayama, Japan.

出版信息

Cancer Sci. 2008 Oct;99(10):1908-15. doi: 10.1111/j.1349-7006.2008.00908.x.

Abstract

Two hundred and sixty-three cases of primary human papillary thyroid carcinoma (PTC) were analyzed. All cases met the following parameters: tumor size > or = 10 mm, no distant metastasis at presentation, and no coexistence of other histological type. The histological features of the solid/trabecular component, encapsulation, tall/columnar cell component and loss of polarity/cohesiveness were utilized to subclassify the 263 cases of PTC into five groups: solid type (15.6%), encapsulated group (9.5%), tall/columnar cell group (7.2%), micropapillary/discohesive group (19.8%) and not-otherwise-specified group (47.9%). We focused on the latter four non-solid groups and compared their prognosis with the solid type. The tall/columnar cell group showed the worst disease-free survival rate (DFS) analyzed by the Kaplan-Meier method, followed by the micropapillary/discohesive group. The not-otherwise-specified group and encapsulated group showed a better DFS rate than the solid type. Cancer-related death was noted in the tall/columnar cell group (21.1%) and micropapillary/discohesive group (3.8%), but not in the other groups. The four non-solid histological groups were further categorized into two prognostic groups: high-risk group (including tall/columnar cell group and micropapillary/discohesive group); and low-risk group (including encapsulated group and not-otherwise-specified group). Their 10-year disease-free survival rates were 78.7% and 93.1%, respectively. In the present study, histological grouping was significantly correlated with prognosis in the multivariate analysis according to the Cox proportional hazards regression model in addition to clinical parameters of extrathyroid invasion and gross lymph node metastasis, which predicts the patient outcome in terms of tumor recurrence and cancer-related death more precisely.

摘要

对263例原发性人甲状腺乳头状癌(PTC)病例进行了分析。所有病例均符合以下参数:肿瘤大小≥10 mm,就诊时无远处转移,且不存在其他组织学类型并存。利用实性/小梁状成分、包膜、高柱状细胞成分以及极性/黏附性丧失的组织学特征,将263例PTC病例分为五组:实性型(15.6%)、包膜型(9.5%)、高柱状细胞型(7.2%)、微乳头/松散型(19.8%)和未另行分类型(47.9%)。我们重点关注后四组非实性型,并将它们的预后与实性型进行比较。采用Kaplan-Meier法分析,高柱状细胞型的无病生存率(DFS)最差,其次是微乳头/松散型。未另行分类型和包膜型的DFS率高于实性型。高柱状细胞型(21.1%)和微乳头/松散型(3.8%)出现了癌症相关死亡,其他组未出现。这四个非实性组织学组进一步分为两个预后组:高危组(包括高柱状细胞型和微乳头/松散型);低危组(包括包膜型和未另行分类型)。它们的10年无病生存率分别为78.7%和93.1%。在本研究中,除了甲状腺外侵犯和大体淋巴结转移等临床参数外,根据Cox比例风险回归模型进行多变量分析时,组织学分组与预后显著相关,这能更准确地根据肿瘤复发和癌症相关死亡预测患者的预后。

相似文献

1
3
Pathologic study and clinical significance of Hürthle cell papillary thyroid carcinoma.
Appl Immunohistochem Mol Morphol. 2004 Dec;12(4):329-37. doi: 10.1097/00129039-200412000-00007.
4
Tall cell variant papillary thyroid carcinoma impacts disease-free survival at the 10 % cut-point on multivariate analysis.
Pathol Res Pract. 2022 Aug;236:154012. doi: 10.1016/j.prp.2022.154012. Epub 2022 Jul 2.
5
Heterogeneous Prognoses for pT3 Papillary Thyroid Carcinomas and Impact of Delayed Risk Stratification.
Thyroid. 2017 Jun;27(6):778-786. doi: 10.1089/thy.2016.0512. Epub 2017 Apr 24.
6
Prognostic Significance of the Proportion of Tall Cell Components in Papillary Thyroid Carcinoma.
World J Surg. 2017 Mar;41(3):742-747. doi: 10.1007/s00268-016-3784-7.
8
Do aggressive variants of papillary thyroid carcinoma have worse clinical outcome than classic papillary thyroid carcinoma?
Eur J Endocrinol. 2018 Sep;179(3):135-142. doi: 10.1530/EJE-17-0991. Epub 2018 Jun 6.
10
Risk of recurrence in a homogeneously managed pT3-differentiated thyroid carcinoma population.
Langenbecks Arch Surg. 2018 May;403(3):325-332. doi: 10.1007/s00423-018-1657-2. Epub 2018 Feb 14.

引用本文的文献

3
Identification of calcium metabolism related score associated with the poor outcome in papillary thyroid carcinoma.
Front Oncol. 2023 Mar 28;13:1108773. doi: 10.3389/fonc.2023.1108773. eCollection 2023.
4
Association of Programmed Death-Ligand 1 Expression with Aggressive Histological Types of Thyroid Carcinoma.
Cancer Manag Res. 2022 Dec 23;14:3539-3550. doi: 10.2147/CMAR.S392475. eCollection 2022.
5
Role of cytotoxic T cells and PD-1 immune checkpoint pathway in papillary thyroid carcinoma.
Front Endocrinol (Lausanne). 2022 Nov 28;13:931647. doi: 10.3389/fendo.2022.931647. eCollection 2022.
9
Updates in the Pathologic Classification of Thyroid Neoplasms: A Review of the World Health Organization Classification.
Endocrinol Metab (Seoul). 2020 Dec;35(4):696-715. doi: 10.3803/EnM.2020.807. Epub 2020 Dec 2.

本文引用的文献

4
Definition of poorly differentiated carcinoma of the thyroid: the Japanese experience.
Endocr Pathol. 2004 Winter;15(4):307-11. doi: 10.1385/ep:15:4:307.
6
Management and outcome of recurrent well-differentiated thyroid carcinoma.
Arch Otolaryngol Head Neck Surg. 2004 Jul;130(7):819-24. doi: 10.1001/archotol.130.7.819.
8
A review of thyroid cancer with intermediate differentiation.
J Surg Oncol. 2004 Apr 1;86(1):44-54. doi: 10.1002/jso.20044.
10
Differentiation, proliferation and retinoid receptor status of papillary carcinoma of the thyroid.
Pathol Int. 2003 Apr;53(4):204-13. doi: 10.1046/j.1320-5463.2003.01456.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验